Key result
A large-scale genetic analysis identified 478 shared genomic loci between eGFR and cardiovascular diseases, and found that genetically predicted higher IGF1R expression was associated with a decreased risk of atrial fibrillation (OR 0.691).
Why the study?
Heart and kidney diseases frequently coexist, but the genetic basis of this relationship remains unclear.
Observational
Yes
Odds Ratio: 0.691 (95% CI 0.528–0.904)
p-value: p=0.007
This large-scale genetic analysis identifies 478 shared genomic loci between kidney function and cardiovascular diseases, highlighting shared biological pathways and potential therapeutic targets like IGF1R for cardiorenal syndrome.
Supports IGF1R investigation as cardiorenal target; leaves open whether modulation improves outcomes in prospective studies.
Heart and kidney diseases frequently coexist, but the genetic basis of this relationship remains unclear. We analyzed genetic data from large-scale studies to investigate how kidney function (estimated glomerular filtration rate, eGFR) and six common cardiovascular diseases share genetic risk factors. Using MiXeR method, and conjunctional false discovery rate (conjFDR) to identify overlapping genetic regions, we found 478 shared genomic loci between eGFR and cardiovascular diseases. These shared genes are involved in tissue development and structure. We also identified 29 genes that could be targeted by existing medications approved by the US Food and Drug Administration, such as PRKAG2, PDE1A, and IGF1R. Among these, genetically predicted higher level of IGF1R expression is associated with a higher eGFR, which reflects good kidney function and is protective against cardiorenal diseases, such as atrial fibrillation, and myocardial infarction. These findings reveal genetic overlap between kidney function and cardiovascular diseases, highlighting potential targets for understanding and treating cardiorenal syndrome.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted an observational in Cardiorenal syndrome (eGFR and cardiovascular diseases). Genetically predicted higher IGF1R expression vs. Lower genetically predicted IGF1R expression was evaluated on Risk of atrial fibrillation (OR 0.691, 95% CI 0.528-0.904, p=0.007). A large-scale genetic analysis identified 478 shared genomic loci between eGFR and cardiovascular diseases, and found that genetically predicted higher IGF1R expression was associated with a decreased risk of atrial fibrillation (OR 0.691).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: